sandoz announc fda reclassifi
manufactur facil voluntari action indic vai follow recent re-
inspect mean mnta/sandoz gener version copaxon mg/ml closer
becom realiti overal level caution teva share base larg part
uncertainti surround number copaxon gener entrant put anoth way
though deep cost cut commend long overdu signific pressur
margin ebitda context net ebitda
ebitda sever turn higher highli lever name group
make difficult us becom construct reiter
neutral rate lower pt multipl unchang see
detail
regard copaxon mg/ml gener alway
recal februari sandoz fill/finish manufactur partner
receiv fda warn letter regard contamin found inject
mcpherson ks facil given today announc regard chang vai statu
follow re-inspect far benign statu facil term fda
green-light new approv near-term approv mnta/sandoz copaxon
mg/ml gener would surpris particularli consid mnta/sandoz
alreadi gener version mg/ml dose copaxon market
thing stand mylan copaxon gener week end
prescript rx written gener version
copaxon mg/ml prior week per im week
third parti rx data product share rx copaxon mg/ml
market compar begin decemb rx
teva brand copaxon mg/ml product show quarter-to-d sequenti
declin versu volum declin sequenti
updat model recal teva guid captur around
cost save plan reduct cost base model
essenti reflect dynam previou estim reflect captur nearli
two-third amount estim also reflect steeper eros
copaxon mg/ml essenti three-way market progress
risk includ copaxon competit gener price risk
teva world largest gener manufactur leader neurolog drug
ep disc
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
note prior estim comparison may applic due pjc updat report line item
reflect singl copaxon mg gener entrant start addit entrant time-frame
consensu estim
compani report factset research pjc estim
page
million except per medicin gener european gener sale row gener medicin third parti consensu incom expens net share consensu teva quarterli annual incom statement
million except ep
sale
sell gener administr
incom loss tax
cog product revenu
expens total revenu
sell gener administr
sell gener administr
reflect singl copaxon mg gener entrant start addit entrant time-frame
teva close acquisit anda segment earli octob reflect full quarter contribut anda
proprietari piper jaffray januari
page
million
net chang asset liabil
acquisit intang
stock option issuanc
proprietari piper jaffray januari
page
million
properti plant equip net
asset defer charg
proprietari piper jaffray januari
page
